Stamminger G, Köppel C, Schaub A, Gärtner I, Tonndorf C, Meyer K, Elix P, Lang B, Beier L
Klinikum Chemnitz gGmbH, Institut für Laboratoriumsmedizin, Germany.
Clin Lab Haematol. 1998 Jun;20(3):143-9. doi: 10.1046/j.1365-2257.1998.00121.x.
The performance of the SE-9000 automated haematology analyser in a laboratory receiving a high number of abnormal specimens from haematological oncology patients was assessed according to formal protocols for the evaluation of blood cell counters. Linearity over a useful working range, precision in clinically important ranges and negligible carry-over were demonstrated in this group of patient samples confirming the results of previous investigators. The comparability of instrument derived differential leucocyte counts from both normal and distributionally abnormal samples with those obtained by visual microscopy using the NCCLS H-20 A protocol was very good. The sensitivity of flags for the detection of immature granulocytes and myeloid blast cells was high and this can be attributed to the incorporation of a new measuring channel (Immature Myeloid Information or IMI channel). The number of unrecognized abnormalities was low and when compared with the poor sensitivity of the routine 100-cell visual differential leucocyte count, the analyser was judged suitable for monitoring patients with haematological malignancies. The performance of flags such as 'left shift' and 'atypical lymphocytes' can be improved by taking into consideration distributional abnormalities such as neutrophilia and lymphocytosis. The trigger level for these flags should be adapted to the clinical need particularly in cases of neutropenia following chemotherapy, and in lymphoproliferative disorders and infection.
根据血细胞计数器评估的正式方案,对一台SE - 9000自动血液分析仪在接收大量血液肿瘤患者异常标本的实验室中的性能进行了评估。在这组患者样本中证实了先前研究人员的结果,即该分析仪在有用的工作范围内具有线性,在临床重要范围内具有精密度,且携带污染可忽略不计。使用NCCLS H - 20 A方案,仪器得出的正常样本和分布异常样本的白细胞分类计数与通过目视显微镜检查获得的结果具有很好的可比性。检测未成熟粒细胞和髓系原始细胞的标记物的敏感性很高,这可归因于纳入了一个新的测量通道(未成熟髓系信息或IMI通道)。未识别出的异常数量很少,并且与常规100细胞目视白细胞分类计数的低敏感性相比,该分析仪被判定适合监测血液系统恶性肿瘤患者。通过考虑诸如中性粒细胞增多和淋巴细胞增多等分布异常情况,可以提高“核左移”和“非典型淋巴细胞”等标记物的性能。这些标记物的触发水平应根据临床需要进行调整,特别是在化疗后出现中性粒细胞减少的情况下,以及在淋巴增殖性疾病和感染中。